Cost-effectiveness and efficacy of an on-site homograft heart-valve bank

To compare the performance and cost-effectiveness of cryopreserved homograft cardiac valves prepared on site to valves prepared commercially.

A review of all patients who received homograft heart valves between January 1990 and December 1993, with cost-effectiveness analysis. Follow-up ranged from 1 to 37 months (mean 12 months).

Tertiary-care adult and pediatric hospitals.

All consecutive patients receiving homograft heart valves in either the aortic or right ventricular outflow tract (RVOT) position since on-site preparation of cryopreserved cardiac valves began in 1990. Forty-three patients received 47 homograft valve replacements: 18 in the aortic position and 29 in the RVOT position. No patients were lost to follow-up.

Valve function as assessed by patient survival, actuarial freedom from reoperation and Doppler echocardiographic assessment of transvalvar gradients and valvar insufficiency. Cost-effectiveness as assessed by a formal evaluation of on-site costs compared with current prices for commercially prepared valves.

There were four operative deaths but no late deaths. Four valves were removed. Freedom from reoperation at 3 years was 100% for aortic valve replacement and 85% for RVOT reconstruction. Echocardiographic follow-up of 34 of the remaining 39 patients showed mild or no insufficiency in 24 valves, moderate insufficiency in 8 valves and severe, but not clinically significant, insufficiency in 2 valves. The cost of on-site preparation of the valves was $1363 compared with $5040 for the commercially prepared valves, a cost saving for the group of $172,819.

On-site preparation is an effective method of preparing cryopreserved cardiac valves and permits significant cost savings.